Cargando…
NOX1, 2, 4, 5: counting out oxidative stress
For decades, oxidative stress has been discussed as a key mechanism of endothelial dysfunction and cardiovascular disease. However, attempts to validate and exploit this hypothesis clinically by supplementing antioxidants have failed. Nevertheless, this does not disprove the oxidative stress hypothe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195911/ https://www.ncbi.nlm.nih.gov/pubmed/21323893 http://dx.doi.org/10.1111/j.1476-5381.2011.01249.x |
_version_ | 1782214176971685888 |
---|---|
author | Wingler, K Hermans, JJR Schiffers, P Moens, AL Paul, M Schmidt, HHHW |
author_facet | Wingler, K Hermans, JJR Schiffers, P Moens, AL Paul, M Schmidt, HHHW |
author_sort | Wingler, K |
collection | PubMed |
description | For decades, oxidative stress has been discussed as a key mechanism of endothelial dysfunction and cardiovascular disease. However, attempts to validate and exploit this hypothesis clinically by supplementing antioxidants have failed. Nevertheless, this does not disprove the oxidative stress hypothesis. As a certain degree of reactive oxygen species (ROS) formation appears to be physiological and beneficial. To reduce oxidative stress therapeutically, two alternative approaches are being developed. One is the repair of key signalling components that are compromised by oxidative stress. These include uncoupled endothelial nitric oxide (NO) synthase and oxidized/heme-free NO receptor soluble guanylate cyclase. A second approach is to identify and effectively inhibit the relevant source(s) of ROS in a given disease condition. A highly likely target in this context is the family of NADPH oxidases. Animal models, including NOX knockout mice and new pharmacological inhibitors of NADPH oxidases have opened up a new era of oxidative stress research and have paved the way for new cardiovascular therapies. LINKED ARTICLES: This article is part of a themed issue on Vascular Endothelium in Health and Disease. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue-3 |
format | Online Article Text |
id | pubmed-3195911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31959112011-10-26 NOX1, 2, 4, 5: counting out oxidative stress Wingler, K Hermans, JJR Schiffers, P Moens, AL Paul, M Schmidt, HHHW Br J Pharmacol Themed Section: Reviews For decades, oxidative stress has been discussed as a key mechanism of endothelial dysfunction and cardiovascular disease. However, attempts to validate and exploit this hypothesis clinically by supplementing antioxidants have failed. Nevertheless, this does not disprove the oxidative stress hypothesis. As a certain degree of reactive oxygen species (ROS) formation appears to be physiological and beneficial. To reduce oxidative stress therapeutically, two alternative approaches are being developed. One is the repair of key signalling components that are compromised by oxidative stress. These include uncoupled endothelial nitric oxide (NO) synthase and oxidized/heme-free NO receptor soluble guanylate cyclase. A second approach is to identify and effectively inhibit the relevant source(s) of ROS in a given disease condition. A highly likely target in this context is the family of NADPH oxidases. Animal models, including NOX knockout mice and new pharmacological inhibitors of NADPH oxidases have opened up a new era of oxidative stress research and have paved the way for new cardiovascular therapies. LINKED ARTICLES: This article is part of a themed issue on Vascular Endothelium in Health and Disease. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue-3 Blackwell Publishing Ltd 2011-10 /pmc/articles/PMC3195911/ /pubmed/21323893 http://dx.doi.org/10.1111/j.1476-5381.2011.01249.x Text en British Journal of Pharmacology © 2011 The British Pharmacological Society |
spellingShingle | Themed Section: Reviews Wingler, K Hermans, JJR Schiffers, P Moens, AL Paul, M Schmidt, HHHW NOX1, 2, 4, 5: counting out oxidative stress |
title | NOX1, 2, 4, 5: counting out oxidative stress |
title_full | NOX1, 2, 4, 5: counting out oxidative stress |
title_fullStr | NOX1, 2, 4, 5: counting out oxidative stress |
title_full_unstemmed | NOX1, 2, 4, 5: counting out oxidative stress |
title_short | NOX1, 2, 4, 5: counting out oxidative stress |
title_sort | nox1, 2, 4, 5: counting out oxidative stress |
topic | Themed Section: Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195911/ https://www.ncbi.nlm.nih.gov/pubmed/21323893 http://dx.doi.org/10.1111/j.1476-5381.2011.01249.x |
work_keys_str_mv | AT winglerk nox1245countingoutoxidativestress AT hermansjjr nox1245countingoutoxidativestress AT schiffersp nox1245countingoutoxidativestress AT moensal nox1245countingoutoxidativestress AT paulm nox1245countingoutoxidativestress AT schmidthhhw nox1245countingoutoxidativestress |